Combined pathogenetic therapy of erectile dysfunction
https://doi.org/10.21886/2308-6424-2023-11-4-72-80
Abstract
Introduction. Erectile dysfunction (ED) is a common condition that reduces the quality of life of numerous men. Therefore, optimising treatment protocols is always a challenge.
Objective. To evaluate the efficacy of "Edelim®" for pathogenetic therapy for erectile dysfunction.
Materials and methods. The study included 67 men (40 – 65 years old) with ED. The patients were divided into two treatment groups: the main group received tadalafil 5 mg PO o.d. + “Edelim®”, the control group received tadalafil 5 mg PO o.d. only. As effectiveness criteria anthropometric studies were used, IIEF-5 scale, metabolic profile blood tests, and systemic endothelial function was assessed.
Results. Over 12 months of therapy, the IIEF-5 score increased by 28.2% in the main group and by 10.3% in the control group. After 12 months in the main group total cholesterol, LDL, triglycerides decreased by 14.8%, 10.7% and 13.9% respectively. The reactive hyperaemia index after 3, 6 and 12 months increased by 6.6%, 10.9% and 22.0%, respectively. In the control group these indices did not change significantly. The main group showed a stable decrease in body mass and waist circumference by an average of 2.6% and 3.8% respectively after 12 months. In the control group, body mass did not change significantly.
Conclusion. Some patients require combination therapy to address metabolic risk factors and disorders, despite the high efficacy of PDE-5 inhibitors in improving erection quality. “Edelim®” is the first product created specifically for long-term combined pathogenetic therapy of ED with metabolic disorders.
About the Authors
S. S. Krasnyak
Lopatkin Scientific Research Institute of Urology and Interventional Radiology
Russian Federation
Russian Federation
Stepan S. Krasnyak — M.D., Cand.Sc.(Med); Leading Researcher, Andrology and Human Reproduction Unit
Moscow
E. A. Efremov
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Evgeny A. Efremov — M.D., Dr.Sc.(Med), Full.Prof.; Prof., Department of Urology, Andrology and Oncology
Moscow
References
1. Klinicheskie rekomendatsii «Erektil'naya disfunktsiya». Minzdrav Rossii; 2021. (In Russian).
2. Gratzke C, Angulo J, Chitaley K, Dai YT, Kim NN, Paick JS, Simonsen U, Uckert S, Wespes E, Andersson KE, Lue TF, Stief CG. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med. 2010;7(1 Pt 2):445-75. Erratum in: J Sex Med. 2010;7(3):1316. DOI: 10.1111/j.1743-6109.2009.01624.x
3. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan; 2023.
4. Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2011;171(20):1797-803. DOI: 10.1001/archinternmed.2011.440
5. Lau KK, Chan YH, Wong YK, Teo KC, Yiu KH, Liu S, Li LS, Shu XO, Ho SL, Chan KH, Siu CW, Tse HF. Garlic intake is an independent predictor of endothelial function in patients with ischemic stroke. J Nutr Health Aging. 2013;17(7):600-4. DOI: 10.1007/s12603-013-0043-6
6. Ku DD, Abdel-Razek TT, Dai J, Kim-Park S, Fallon MB, Abrams GA. Garlic and its active metabolite allicin produce endothelium- and nitric oxide-dependent relaxation in rat pulmonary arteries. Clin Exp Pharmacol Physiol. 2002;29(1-2):84-91. DOI: 10.1046/j.1440-1681.2002.03596.x
7. Sun X, Ku DD. Allicin in garlic protects against coronary endothelial dysfunction and right heart hypertrophy in pulmonary hypertensive rats. Am J Physiol Heart Circ Physiol. 2006;291(5):H2431-8. DOI: 10.1152/ajpheart.00384.2006
8. Szulińska M, Kręgielska-Narożna M, Świątek J, Styś P, Kuźnar-Kamińska B, Jakubowski H, Walkowiak J, Bogdański P. Garlic extract favorably modifies markers of endothelial function in obese patients -randomized double blind placebo-controlled nutritional intervention. Biomed Pharmacother. 2018;102:792-797. DOI: 10.1016/j.biopha.2018.03.131
9. McIver DJ, Grizales AM, Brownstein JS, Goldfine AB. Risk of Type 2 Diabetes Is Lower in US Adults Taking Chromium-Containing Supplements. J Nutr. 2015;145(12):2675-82. DOI: 10.3945/jn.115.214569
10. Hua Y, Clark S, Ren J, Sreejayan N. Molecular mechanisms of chromium in alleviating insulin resistance. J Nutr Biochem. 2012;23(4):313-9. DOI: 10.1016/j.jnutbio.2011.11.001
11. Davis CM, Vincent JB. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry. 1997;36(15):4382-5. DOI: 10.1021/bi963154t
12. Chen G, Liu P, Pattar GR, Tackett L, Bhonagiri P, Strawbridge AB, Elmendorf JS. Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol. 2006;20(4):857-70. DOI: 10.1210/me.2005-0255
13. De G, Yang M, Cai W, Zhao Q, Lu L, Chen A. Salvia miltiorrhiza augments endothelial cell function for ischemic hindlimb recovery. Biol Chem. 2023. Epub ahead of print. PMID: 36869860. DOI: 10.1515/hsz-2022-0316.
14. Ota A, Ulrih NP. An Overview of Herbal Products and Secondary Metabolites Used for Management of Type Two Diabetes. Front Pharmacol. 2017;8:436. DOI: 10.3389/fphar.2017.00436
15. Lambeau KV, McRorie JW Jr. Fiber supplements and clinically proven health benefits: How to recognize and recommend an effective fiber therapy. J Am Assoc Nurse Pract. 2017;29(4):216-223. DOI: 10.1002/2327-6924.12447
16. Kyzlasov P.S., Volokitin E.V., Mustafayev A.T., Pomeshkin E.V. Application of the complex Edelim in pathogenetic management of patients with erectile dysfunction. Urology reports (St. - Petersburg). 2021;11(3):219-225. (In Russian) DOI: 10.17816/uroved74801
Review
For citations:
Krasnyak S.S., Efremov E.A. Combined pathogenetic therapy of erectile dysfunction. Urology Herald. 2023;11(4):72-80. (In Russ.) https://doi.org/10.21886/2308-6424-2023-11-4-72-80
Views:
872
Email this article 
